Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis - A Randomized Controlled Trial.

Institute of Liver and Biliary Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Recent Gastrointestinal bleeding within 7 days
•2.Systemic arterial hypertension ( >160/90mmhg)
•3.Presence of hepatocellular carcinoma or portal vein thrombosis, Budd-chiari syndrome.
•4.Pregnancy
•5.No use of drugs affecting systemic hemodynamics 7 days prior to enrolment
•6.Patients with Cardiovascular disease (NYHA > II) or chronic obstructive pulmonary disease
•7.Refusal to participate
•8.Known or suspected hypersensitivity to albumin
•9.Prior TIPS
•10.Post liver or kidney transplantation
•11.Patients enrolled in other clinical trials
•12.Extrahepatic malignancy
•13.Patients on cardiac glycosides like digoxin, phenylephrine, ephedrine, thyroid hormones,ergot derivatives, salt retaining steroids like fludrocortisone, MAO inhibitors, alpha blockers metformin and ranitidine (known to have interactions with midodrine)
•14.Patients with intrinsic kidney disease, organ nephropathy and CKD stage 4 and
•15.MELD > 30 and extremely moribend patient

发起方